Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature

Eryilmaz M. K., Mutlu H., Salim D. K., Musri F. Y., COŞKUN H. Ş.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.22, sa.6, ss.806-810, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 6
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1177/1078155215611048
  • Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.806-810
  • Anahtar Kelimeler: Bevacizumab, metastatic colorectal cancer, posterior reversible leukoencephalopathy syndrome, REVERSIBLE ENCEPHALOPATHY SYNDROME, PATIENT, CHEMOTHERAPY, THERAPY, REGIMEN, SPECT
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Posterior reversible leukoencephalopathy syndrome (PRES) is a syndrome characterized by headache, hypertension, confusion, visual disturbance, and seizures accompanied by subcortical vasogenic edema, predominantly involving the parietal and occipital lobes. The syndrome is usually described in malignant hypertension, eclampsia, renal failure, immunosuppressive, and cytotoxic chemotherapies. Bevacizumab, a monoclonal antibody that binds to the vascular endothelial growth factor (VEGF) has been linked to PRES. We carried out review of reports documenting the occurrence of PRES in patients receiving bevacizumab. This literature review was conducted by utilizing PubMed Database. If early diagnosed, PRES is reversible. We present a case of fatal PRES-associated coma induced by bevacizumab in metastatic colorectal cancer.